title: Evaluation of the relationship between elevated vancomycin trough concentrations and increased efficacy and/or toxicity.
abstract: Isolation of Staphylococcus aureus with minimum inhibitory concentrations, 1 to 2 mg/L, suggests increasing vancomycin trough ranges, from 10 to 20 mg/L or even higher. Vancomycin troughs from 604 treatment courses from 560 patients with suspected or actual Gram-positive infection were analyzed with focus on potential toxicity/efficacy. Trough concentrations were required to be drawn within 15 to 45 minutes before the administration of at least the third vancomycin dose. Patients were retrospectively evaluated for their total daily dose and milligrams per kilograms per vancomycin dose. Data on the duration of vancomycin therapy, days to a normal temperature, and white blood cells were obtained. Data were stratified by trough concentration as <5, 5 to 10, and >10 mg/L to determine whether there was any relationship between response and trough concentration. Demographic data were obtained in 560 patients with 604 vancomycin treatment courses. For 361 patients with 379 separate treatment courses of vancomycin therapy no other nephrotoxic antimicrobial agent had been used. The greatest risk of vancomycin nephrotoxicity correlated with the duration of treatment. Using the log time to normal temperature, white blood cell count, heart rate, outcome from vancomycin therapy was assessed and no relationship could be demonstrated for the three vancomycin trough strata using analysis of variance (F < 2.62 for all parameters; p > .05). These data indicate that vancomycin trough elevation may not guarantee treatment success and that there may be no real benefit from higher vancomycin trough concentrations in thermal injury patients with burns <20% TBSA.
authors.affiliation: Nathan Speare Regional Burn Treatment Center, Crozer-Chester Medical Center, Upland, Pennsylvania 19013, USA. Bruce.ackerman@crozer.org
authors.forename: Bruce H
authors.initials: BH
authors.lastname: Ackerman
authors.forename: Robert E
authors.initials: RE
authors.lastname: Guilday
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Reigart
authors.forename: Mary L
authors.initials: ML
authors.lastname: Patton
authors.forename: Linwood R
authors.initials: LR
authors.lastname: Haith
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D002056:Burns / Q000382:microbiology*; D016009:Chi-Square Distribution; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014640:Vancomycin / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin